Peter B.  Silverman net worth and biography

Peter Silverman Biography and Net Worth

EVP, Chief Operating Officer, & General Counsel of Merus

Peter B. Silverman, J.D. has served the Company since 2014, first as outside counsel, as Chief Operating Officer since January 1, 2023, as Head of Utrecht from April 2020 to January 1, 2023, as General Counsel since February 2018 and our Chief Intellectual Property Officer and Head of US Legal since February 2017.

His responsibilities include management of the Company’s operations, legal and intellectual property, information technology, facilities and human resource matters, and management and operations of the headquarters in Utrecht. Prior to joining Merus, Mr. Silverman was a Partner at Kirkland & Ellis LLP, where he represented numerous life sciences companies concerning an array of legal matters and technologies. Mr. Silverman was an associate at Kaye Scholer LLP (now Arnold & Porter Kaye Scholer LLP), and prior to that Mr. Silverman also served as judicial law clerk to U.S. District Court Judge Anne E. Thompson of the District of New Jersey. He holds a J.D. from Fordham University School of Law, graduating magna cum laude and Order of the Coif. He is admitted to practice law in New York. Mr. Silverman also holds a B.A. in biology from the University of Rochester.

How old is Peter B. Silverman?

Mr. Silverman is currently 46 years old. There are 5 older executives and no younger executives at Merus. The oldest executive at Merus is Mr. Gregory D. Perry, Chief Financial Officer, who is 64 years old. Learn More on Peter B. Silverman's age.

How do I contact Peter B. Silverman?

The corporate mailing address for Mr. Silverman and other Merus executives is YALELAAN 62, UTRECHT P7, 3584 CM. Merus can also be reached via phone at (130) 253-8800 and via email at [email protected]. Learn More on Peter B. Silverman's contact information.

Has Peter B. Silverman been buying or selling shares of Merus?

Peter B. Silverman has not been actively trading shares of Merus during the past quarter. Learn More on Peter B. Silverman's trading history.

Who are Merus' active insiders?

Merus' insider roster includes Lex Bakker (SVP), Kruif de Kruif (SVP), Sven Lundberg (President, Chief Executive Officer, Executive Director), and Peter Silverman (EVP, Chief Operating Officer, & General Counsel). Learn More on Merus' active insiders.

Are insiders buying or selling shares of Merus?

In the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 47,376 shares worth more than $1,969,643.70. The most recent insider tranaction occured on June, 27th when COO Peter B. Silverman sold 10,000 shares worth more than $600,000.00. Insiders at Merus own 4.6% of the company. Learn More about insider trades at Merus.

Information on this page was last updated on 6/27/2024.

Peter B. Silverman Insider Trading History at Merus

See Full Table

Peter B. Silverman Buying and Selling Activity at Merus

This chart shows Peter B. Silverman's buying and selling at Merus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Merus Company Overview

Merus logo
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Read More

Today's Range

Now: $54.50
Low: $53.50
High: $54.90

50 Day Range

MA: $50.92
Low: $47.19
High: $54.50

2 Week Range

Now: $54.50
Low: $22.01
High: $61.61

Volume

340,271 shs

Average Volume

688,089 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12